Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

Future Horizons in Lung Cancer

1 - 2 Sep 2016

Royal Society of Medicine, London, United Kingdom of Great Britain and Northern Ireland

Immunotherapy and treatment advances in small cell lung cancer

Prof Dean Fennell - University of Leicester, Leicester, UK

Immunotherapy and treatment advances in small cell lung cancer ( Prof Dean Fennell - University of Leicester, Leicester, UK )

Lung cancer screening in the UK

Prof John Field - University of Liverpool, Liverpool, UK

Lung cancer screening in the UK ( Prof John Field - University of Liverpool, Liverpool, UK )

Screening, surgical cure and new developments: Future smart surgical approaches for brain mets

Dr Francesco Di Meco - Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy

Screening, surgical cure and new developments: Future smart surgical approaches for brain mets ( Dr Francesco Di Meco - Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy )

NSCLC biology and new therapies: Immunotherapies

Dr Rafael Rosell - Catalan Institute of Oncology, Barcelona, Spain

NSCLC biology and new therapies: Immunotherapies ( Dr Rafael Rosell - Catalan Institute of Oncology, Barcelona, Spain )

NSCLC biology and new therapies: Reversing resistance

Prof Michael Seckl - Imperial College London, London, UK

NSCLC biology and new therapies: Reversing resistance ( Prof Michael Seckl - Imperial College London, London, UK )

Screening, surgical cure and new developments: Current state of the art surgery

Dr Ugo Pastorino - Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Screening, surgical cure and new developments: Current state of the art surgery ( Dr Ugo Pastorino - Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy )

Screening, surgical cure and new developments: Q & A

Dr Henschke, Prof Field, Dr Pastorino, Dr Di Meco

Screening, surgical cure and new developments: Q & A ( Dr Henschke, Prof Field, Dr Pastorino, Dr Di Meco )

NSCLC biology and new therapies: Q & A

Prof Downward, Dr Rosell, Prof Seckl

NSCLC biology and new therapies: Q & A ( Prof Downward, Dr Rosell, Prof Seckl )

NSCLC biology and new therapies: Animal models of lung cancer

Prof Julian Downward - The Francis Crick Institute, London, UK

NSCLC biology and new therapies: Animal models of lung cancer ( Prof Julian Downward - The Francis Crick Institute, London, UK )

Immunotherapy in lung cancer: Q & A

Prof Giuseppe Giaccone and Dr Olivier Pardo

Immunotherapy in lung cancer: Q & A ( Prof Giuseppe Giaccone and Dr Olivier Pardo )

Tumour heterogeneity and the impact on patient care

Dr Nicholas McGranahan - The Francis Crick Institute, London, UK

Tumour heterogeneity and the impact on patient care ( Dr Nicholas McGranahan - The Francis Crick Institute, London, UK )

Screening, surgical cure and new developments: How to avoid false positives in lung cancer screening

Dr Claudia Henschke - Mount Sinai Hospital, New York, USA

Screening, surgical cure and new developments: How to avoid false positives in lung cancer screening ( Dr Claudia Henschke - Mount Sinai Hospital, New York, USA )

Screening, surgical cure and new developments: How to organise a national screening programme

Prof John Field - University of Liverpool, Liverpool, UK

Screening, surgical cure and new developments: How to organise a national screening programme ( Prof John Field - University of Liverpool, Liverpool, UK )

Omics, early detection and novel therapies: Q & A

Dr Murrell and Dr Pardo

Omics, early detection and novel therapies: Q & A ( Dr Murrell and Dr Pardo )

Immunotherapy in NSCLC

Prof Giuseppe Giaccone - Georgetown University, Washington DC, USA

Immunotherapy in NSCLC ( Prof Giuseppe Giaccone - Georgetown University, Washington DC, USA )

Immunotherapy in SCLC

Prof Dean Fennell - University of Leicester, Leicester, UK

Immunotherapy in SCLC ( Prof Dean Fennell - University of Leicester, Leicester, UK )

Omics, early detection and novel therapies: Metabolomics

Dr Olivier Pardo - Imperial College London, London, UK

Omics, early detection and novel therapies: Metabolomics ( Dr Olivier Pardo - Imperial College London, London, UK )

Small cell lung cancer: Q & A

Prof Gordon McVie, Prof Caroline Dive, Dr Fiona Blackhall and Dr Marianne Nicolson

Small cell lung cancer: Q & A ( Prof Gordon McVie, Prof Caroline Dive, Dr Fiona Blackhall and Dr Marianne Nicolson )

Omics, early detection and novel therapies: Epigenetic studies

Dr Adele Murrell - University of Bath, Bath, UK

Omics, early detection and novel therapies: Epigenetic studies ( Dr Adele Murrell - University of Bath, Bath, UK )

Small cell lung cancer: New therapies

Dr Fiona Blackhall - The Christie NHS Foundation Trust, Manchester, UK

Small cell lung cancer: New therapies ( Dr Fiona Blackhall - The Christie NHS Foundation Trust, Manchester, UK )

Small cell lung cancer: Current standards of care

Dr Marianne Nicolson - Aberdeen Royal Infirmary, Aberdeen, UK

Small cell lung cancer: Current standards of care ( Dr Marianne Nicolson - Aberdeen Royal Infirmary, Aberdeen, UK )

We should use PDL1 and other biomarkers for selecting patients for immune checkpoint therapies

Dr Mary O’Brien - The Royal Marsden NHS Foundation Trust, London, UK

We should use PDL1 and other biomarkers for selecting patients for immune checkpoint therapies ( Dr Mary O’Brien - The Royal Marsden NHS Foundation Trust, London, UK )

Maintenance in NSCLC: Arguments against

Dr Benjamin Besse - Institut Gustave Roussy, Paris, France

Maintenance in NSCLC: Arguments against ( Dr Benjamin Besse - Institut Gustave Roussy, Paris, France )

Maintenance in NSCLC: Arguments for

Dr Jaishree Bhosle - The Royal Marsden NHS Foundation Trust, London, UK

Maintenance in NSCLC: Arguments for ( Dr Jaishree Bhosle - The Royal Marsden NHS Foundation Trust, London, UK )

Maintenance in NSCLC: Q & A

Dr Besse and Dr Bhosle

Maintenance in NSCLC: Q & A ( Dr Besse and Dr Bhosle )

We should not use PDL1 and other biomarkers for selecting patients for immune checkpoint therapies

Prof Gordon McVie - King's College London, London, UK

We should not use PDL1 and other biomarkers for selecting patients for immune checkpoint therapies ( Prof Gordon McVie - King's College London, London, UK )

Using PDL1 and other biomarkers in patient selection for immunology: Q & A

Dr O'Brien and Prof McVie

Using PDL1 and other biomarkers in patient selection for immunology: Q & A ( Dr O'Brien and Prof McVie )

Current standards of care in advanced NSCLC

Dr Frances Shepherd - The Princess Margaret Cancer Centre, Toronto, Canada

Current standards of care in advanced NSCLC ( Dr Frances Shepherd - The Princess Margaret Cancer Centre, Toronto, Canada )

Imaging and novel PET tracers: Q & A

Dr Giulia Veronesi and Prof Tony Ng

Imaging and novel PET tracers: Q & A ( Dr Giulia Veronesi and Prof Tony Ng )

Imaging and novel PET tracers: The future

Prof Tony Ng - King's College London, London, UK

Imaging and novel PET tracers: The future ( Prof Tony Ng - King's College London, London, UK )

Imaging and novel PET tracers: State of the art

Dr Giulia Veronesi - Humanitas Research Hospital, Milan, Italy

Imaging and novel PET tracers: State of the art ( Dr Giulia Veronesi - Humanitas Research Hospital, Milan, Italy )

Radiotherapy - what's new? Q & A

Dr David Landau and Prof Corinne Favire-Finn

Radiotherapy - what's new? Q & A ( Dr David Landau and Prof Corinne Favire-Finn )

Radiotherapy in lung cancer: Future directions

Dr David Landau - Guy's and St Thomas' NHS Trust, London, UK

Radiotherapy in lung cancer: Future directions ( Dr David Landau - Guy's and St Thomas' NHS Trust, London, UK )

Radiotherapy in lung cancer: Current state of the art

Prof Corinne Faivre-Finn - Christie NHS Foundation Trust, Manchester, UK

Radiotherapy in lung cancer: Current state of the art ( Prof Corinne Faivre-Finn - Christie NHS Foundation Trust, Manchester, UK )

Metabolomics: Reversing drug resistance

Dr Olivier Pardo - Imperial College London, London, UK

Metabolomics: Reversing drug resistance ( Dr Olivier Pardo - Imperial College London, London, UK )

Tumour heterogeneity and the impact on patient care

Dr Nicholas McGranahan - The Francis Crick Institute, London, UK

Tumour heterogeneity and the impact on patient care ( Dr Nicholas McGranahan - The Francis Crick Institute, London, UK )

Developing new models in SCLC

Prof Caroline Dive - Cancer Research UK Manchester Institute, Manchester, UK

Developing new models in SCLC ( Prof Caroline Dive - Cancer Research UK Manchester Institute, Manchester, UK )

Future of imaging in lung cancer

Prof Tony Ng - King's College London, London, UK

Future of imaging in lung cancer ( Prof Tony Ng - King's College London, London, UK )

Understanding the mechanisms of immunotherapy in lung cancer

Dr Rafael Rosell - Catalan Institute of Oncology, Barcelona, Spain

Understanding the mechanisms of immunotherapy in lung cancer ( Dr Rafael Rosell - Catalan Institute of Oncology, Barcelona, Spain )

PDL1 and other biomarkers for selecting patients for immune checkpoint therapies

Dr Mary O'Brien - The Royal Marsden NHS Foundation Trust, London, UK

PDL1 and other biomarkers for selecting patients for immune checkpoint therapies ( Dr Mary O'Brien - The Royal Marsden NHS Foundation Trust, London, UK )

State of the art imaging and lung cancer management

Dr Giulia Veronesi - Humanitas Research Hospital, Milan, Italy

State of the art imaging and lung cancer management ( Dr Giulia Veronesi - Humanitas Research Hospital, Milan, Italy )

Future smart surgical approaches for brain metastases

Dr Francesco Di Meco - Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy

Future smart surgical approaches for brain metastases ( Dr Francesco Di Meco - Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy )

Future directions in radiation medicine

Dr David Landau - Guy's and St Thomas' NHS Trust, London, UK

Future directions in radiation medicine ( Dr David Landau - Guy's and St Thomas' NHS Trust, London, UK )

How to avoid false positives in lung cancer

Dr Claudia Henschke - Mount Sinai Hospital, New York, USA

How to avoid false positives in lung cancer ( Dr Claudia Henschke - Mount Sinai Hospital, New York, USA )

Current state of the art radiotherapy in lung cancer

Prof Corinne Faivre-Finn - The Christie NHS Foundation Trust, Manchester, UK

Current state of the art radiotherapy in lung cancer ( Prof Corinne Faivre-Finn - The Christie NHS Foundation Trust, Manchester, UK )

Maintenance in NSCLC

Dr Benjamin Besse - Institut Gustave Roussy, Paris, France

Maintenance in NSCLC ( Dr Benjamin Besse - Institut Gustave Roussy, Paris, France )

Recent advances and emerging therapies in lung cancer

Prof McVie, Prof Dive, Dr Nicolson and Prof Seckl

Recent advances and emerging therapies in lung cancer ( Prof McVie, Prof Dive, Dr Nicolson and Prof Seckl )

More from ecancer